Musical Attention Control and Executive Function Training for Adults With MDD
NCT05694156, Not applicable, Completed, Unity Health Toronto
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Musical Attention Control and Executive Function Training for Adults With MDD | ClinicalTrials.gov |
| NCT number | NCT05694156 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 18 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Unity Health Toronto | ClinicalTrials.gov |
| Conditions | Major Depressive Disorder, Cognitive Dysfunction, Suicide | ClinicalTrials.gov |
| Interventions | Music-based cognitive training | ClinicalTrials.gov |
| First posted | 2023-01-23 | ClinicalTrials.gov |
| Last updated | 2025-03-04 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in inhibition using the Go/No Go Task | From baseline to 8-weeks | This cognitive task measures response time, accuracy, commission errors, omission errors, and reaction time variability. | ClinicalTrials.gov |
| Primary | Change in working memory capacity using the Digit Span Forward and Backward Test | From baseline to 8-weeks | This cognitive task measures span length, correct recall, error rate, and reaction time. | ClinicalTrials.gov |
| Primary | Change in cognitive flexibility and executive control using the Shifting Attention test | From baseline to 8-weeks | This cognitive task measures the ability to shift attention between different stimuli, assessing the speed and accuracy with which the individual can shift their attention and switch between different rules. | ClinicalTrials.gov |
| Primary | Change in visual attention and task switching using the Trail Making A and B test | From baseline to 8-weeks | This cognitive task measures the time to complete the task and errors made. In Trail Making Test A, a longer completion time and higher number of errors can indicate difficulties with processing speed and attention. In Trail Making Test B, a longer completion time and a higher number of errors on Trail Making Test B, compared to Trail Making Test A, can indicate difficulties with cognitive flexibility, mental shifting, and attention. | ClinicalTrials.gov |
| Primary | Change in selective attention using the Stroop Test | From baseline to 8-weeks | This cognitive task measures the time to complete the task and errors made. A longer completion time and a higher number of errors can indicate difficulty with selective attention and mental flexibility. | ClinicalTrials.gov |
| Secondary | Change in suicidal ideation using the Beck Scale for Suicide Ideation (BSSI) | From baseline to 8-weeks | A 21-item self-report scale that quantifies suicidal ideation. The BSSI is a Likert-style questionnaire, where each item is rated on a scale from 0 to 3, with higher scores indicating a greater severity of suicidal thoughts and behaviours. The minimum possible score on the BSSI is 0, which would indicate the absence of suicidal ideation. The maximum possible score is 63, which would indicate a high level of severity of suicidal thoughts and behaviours. | ClinicalTrials.gov |
| Secondary | Changes in affect using the Positive and negative affect schedule - short form (PNAS-SF) | From baseline to 8-weeks | A 10-item scale to assess the experience of positive and negative emotions/feelings. Each item is rated on a 5-point Likert scale, ranging from 1 (very slightly or not at all) to 5 (extremely). The minimum possible score on the PNAS-SF for positive affect is 10, which would indicate the absence of positive affect. The maximum possible score is 50, which would indicate a high level of positive affect. The minimum possible score on the PNAS-SF for negative affect is 10, which would indicate the absence of negative affect. The maximum possible score is 50, which would indicate a high level of negative affect. | ClinicalTrials.gov |
| Secondary | Changes in depression symptoms using the Quick Inventory of Depressive Symptomatology - self-report (QIDS-SR). | From baseline to 8-weeks | A 16-item validated depression scale. Each item is rated on a 4-point Likert scale, ranging from 0 (not at all) to 3 (severe). The minimum possible score on the QID-SR is 0, which would indicate the absence of depression. The maximum possible score is 48, which would indicate a high level of depression severity. | ClinicalTrials.gov |
| Secondary | Changes in quality of life using the Quality of Life Scale (QOLS) | From baseline to 8-weeks | A validated 16-item scale to assess quality of life. Each item is rated on a 7-point Likert scale , ranging from 1 (terrible) to 7 (delighted). The minimum possible score on the QOLS is 16, which would indicate poor quality of life. The maximum possible score is 112, which would indicate excellent quality of life. | ClinicalTrials.gov |
| Secondary | Feasibility and acceptability of music-based cognitive training | From baseline to 8-weeks | Feasibility and Acceptability survey and interview created in-house with questions designed to collect quantitative and qualitative feedback from participants with respect to the feasibility and acceptability of the music-based cognitive training intervention. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 13
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 15529285 | BACKGROUND | PubMed |
| 19673815 | BACKGROUND | PubMed |
| 21716636 | BACKGROUND | PubMed |
| 22781400 | BACKGROUND | PubMed |
| 25439523 | BACKGROUND | PubMed |
| 25660985 | BACKGROUND | PubMed |
| 25702365 | BACKGROUND | PubMed |
| 25773636 | BACKGROUND | PubMed |
| 25774137 | BACKGROUND | PubMed |
| 27616997 | BACKGROUND | PubMed |
| 29345866 | BACKGROUND | PubMed |
| 30042703 | BACKGROUND | PubMed |
| 30468135 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Go/No-Go Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Task Switching Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)